Oddo BHF Asset Management Sas Takes $6.41 Million Position in Natera, Inc. $NTRA

Oddo BHF Asset Management Sas bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the first quarter, Holdings Channel reports. The institutional investor bought 32,053 shares of the medical research company’s stock, valued at approximately $6,410,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Horizon Investments LLC grew its holdings in Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares during the period. Sound Income Strategies LLC increased its stake in Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. raised its holdings in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares during the period. Parallel Advisors LLC raised its holdings in shares of Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares during the period. Finally, First Horizon Corp boosted its position in shares of Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after purchasing an additional 51 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on NTRA. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday, July 15th. UBS Group set a $260.00 price objective on Natera in a research note on Wednesday, June 24th. Finally, Sanford C. Bernstein started coverage on Natera in a report on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $267.83.

More Natera News

Here are the key news stories impacting Natera this week:

• Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
• Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
• Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.

Insiders Place Their Bets

In other Natera news, Director Roelof Botha sold 78,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. The trade was a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 3,405 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the sale, the insider directly owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 178,862 shares of company stock worth $40,416,335 in the last 90 days. Company insiders own 5.05% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $253.82 on Thursday. The stock has a market capitalization of $36.35 billion, a P/E ratio of -155.72 and a beta of 1.51. The company has a 50-day moving average price of $244.16 and a 200-day moving average price of $221.65. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.